Fig. 4
From: Active immunization with Tocilizumab mimotopes induces specific immune responses
Peptides compete with rIL-6R to Tocilizumab. To demonstrate the peptides and original antigen can share the same binding site of Tocilizumab, peptide competitive binding assay was then performed. ELISA plates were coated with rIL-6R (0.1 μg/ml). After the plates were washed and blocked, synthesized peptides (10 μg/ml) and Tocilizumab (1 μg/ml) were co-incubated. Then Tocilizumab was detected with HRP–conjugated Fc-specific goat ant-human IgG. The results showed that Tocilizumab binding rate decreased significantly after we added peptides to compete with rIL-6R to Tocilizumab (mean ± SD, *, P < 0.05; **, P < 0.005; ***, p < 0.001)